Its also taken once a week at the same time and day with a dosage increase after every 4 weeks
State boards vary widely in enforcement, and the FDAs current framework doesnt cleanly map onto hybrid telehealth-compounding platforms
Conducting a meta-analysis on the efficacy and safety of novel therapeutic agents like Resmetirom, FGF21 analogs, and GLP-1 agonists for MASLD and MASH is essential for offering a comparative evaluation among these therapeutic options
Thats not where the risk-benefit lies. Given that health insurance wont cover GLP-1s if you arent obese, dont have type 2 diabetes, or arent overweight with cardiovascular disease, the cost can add up for years before you know whether the spend was really worth it
The following resources provide additional context across different evaluation frameworks: A 2026 informational overview examining MEDVi's compounded tirzepatide GLP-1 telehealth program, regulatory classification, and pricing disclosures provides additional context on the platform's tirzepatide-specific offerings and enrollment considerations
doi: 10.1093/eurheartj/ehad192